Isotopically labelledEnsartinib-13C2-d6Cat. No. P-E055-002Family · Pharmaceutical analytical standards
Ensartinib
An oral inhibitor of the ALK kinase for advanced ALK-positive non-small cell lung cancer, approved first in China, in 2020, and then in the United States, in 2024. This family brings together labelled standards, nitrosamines and other impurities.
Did you know?Its target, ALK, takes its name from anaplastic large-cell lymphoma, the cancer in which it was discovered in 1994; in the lung it is involved in about 3-5% of non-small cell cancers.
Isotopically labelledEnsartinib-13C2-d6Cat. No. P-E055-002
Isotopically labelledEnsartinib-d6Cat. No. P-E055-003
NitrosamineN-Nitroso EnsartinibCat. No. P-E055-004
ImpurityEnsartinib(X-396)Cat. No. P-E055-005CAS 1370651-20-9No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.